What Ziconotide is
Ziconotide is a cone-snail-derived peptide medicine used in approved severe pain-management contexts through N-type calcium channel blockade.
Ziconotide is grouped under Approved / Clinical on PeptideFactCheck because it is one of the clearest examples of an unusual peptide source becoming a real regulated medicine.
The useful starting point is to separate the molecule itself from the internet story around it. It is one of the clearest examples of an unusual peptide source becoming a real regulated medicine.
Why people keep looking it up
It is one of the clearest examples of an unusual peptide source becoming a real regulated medicine.
Ziconotide is a cone-snail-derived peptide medicine used in approved severe pain-management contexts through N-type calcium channel blockade.
Ziconotide tends to stay in the conversation because it touches a familiar public theme: conopeptide, calcium channel blocker, and pain medicine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide analgesic with direct human evidence.
Human trials and labeling support specific approved use in severe pain contexts.
Mechanism follows calcium-channel blockade and pain-transmission biology.
Why this page carries the current tier: Approved peptide analgesic with direct human evidence.
The current seed trail for Ziconotide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a high-risk pain-management context, not a general wellness peptide.
FDA-approved ziconotide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Ziconotide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Ziconotide is CID 16135415. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16135415
- Formula
- C102H172N36O32S7
- Molecular weight
- 2639.2
- InChIKey
- BPKIMPVREBSLAJ-QTBYCLKRSA-N
Matched synonyms include Ziconotide, 107452-89-1, SNX-111, omega-Conotoxin M VIIA, Ziconotida, omega-Conopeptide MVIIA (Conus), DTXSID60883174, 7I64C51O16.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Ziconotide returns 13 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Ziconotide returns 489 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- PRIALT
- Generic names
- ZICONOTIDE ACETATE
- Routes
- INTRATHECAL
- Application numbers
- NDA021060
Indications and usage. 1 INDICATIONS AND USAGE PRIALT (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. PRIALT (ziconotide) solution, intrathecal infusion is an N-type calcium channel antagonist i...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Cognitive and neuropsychiatric adverse reactions – Cognitive impairment and severe neuropsychiatric symptoms may occur with PRIALT use. ( 5.1 ) Meningitis and other infections – Patients, caregivers, and healthcare providers must be aware of the signs and symptoms of meningitis, including but not limited to fever, headache, stiff neck, altered mental status (e.g., lethargy, confusion, diso...
Contraindications. 4 CONTRAINDICATIONS PRIALT is contraindicated in patients with a known hypersensitivity to ziconotide or any of its formulation components. PRIALT is contraindicated in patients with any other concomitant treatment or medical condition that would render intrathecal administration hazardous. Contraindications to the use of intrathecal analgesia include the presence of infection at the microinfusion injection site, un...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.